I. Proper recognition of Her2 positive breast cancer:
It’s a special type of breast cancer. Her2 is an original cancer gene that is overexpressed or amplified in about 15-20% of breast cancer patients, which is Her2 positive breast cancer. This type of breast cancer is relatively more intrusive and prone to relapse and transfer. 2. The Epidemic Her2 Gene is located on the 17q21 of the human chromosomal, which causes overexpression of Her2 protein when the gene mutates, expands or regulates abnormalities. These excess Her2 proteins form a congener-dipleomer on the surface of the cell, or are formed with other skin growth factors receptors. They activate downstream signals, such as phosphorous resin septol3, hormone enzyme (PI3K), protein hormone B (Akt) and filamentary active protein enzyme (MAPK), and promote cell growth, survival, transport and invasion.
III. How to diagnose? Her2 positive breast cancer has similar clinical manifestations and other types of breast cancer. Breast pain-free swelling usually occurs, with a hard, undefined border and low mobility. Some of the patients are likely to be exposed to nipple spills, changes in breast skin orange skin (skin edema-like orange skin), dimples (tumour stress and cooper dysentery, dents in holding skin). This is determined mainly by two tests: IHC and FISH. If the results of the immunisation group examination were 3+, the test could be Her2 positive; if it was 2+, further FISH testing would be required to determine whether the Her2 gene was expanded. IV. Treatment:
Target treatment.
2 Chemotherapy: On the basis of target-oriented treatment, there is usually a need to combine chemotherapy to kill cancer cells by disrupting their division and breeding.
3. Endocrine treatment (for some patients): For hormonal receptor-positive Her2-positive breast cancer, endocrine treatment is also available at the same time to regulate the hormonal levels in the body and to inhibit tumour growth.
4. Prognosis: The prognosis of Her2-positive breast cancer has improved considerably with the application of a variety of treatments, including target-oriented treatment. However, the risk of relapse remains relatively high compared to Her2-negative breast cancer, which requires rigorous regular follow-up and monitoring.
Breast cancer
